3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Neoplasms
10
Carcinoma, Non-Small-Cell Lung
7
Ovarian Neoplasms
6
Carcinoma, Transitional Cell
6
Squamous Cell Carcinoma of Head and Neck
5
Neoplasm Metastasis
5
Carcinoma, Renal Cell
5
Breast Neoplasms
4
Triple Negative Breast Neoplasms
3
Recurrence
3
Melanoma
3
Colorectal Neoplasms
3
Urinary Bladder Neoplasms
2
Sarcoma
2
Lymphoma, Follicular
2
Lymphoma
2
Central Nervous System Neoplasms
2
Uveal Melanoma
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Solid Tumors
1
Skin Neoplasms
1
Sezary Syndrome
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Peritoneal Neoplasms
1
Pancreatic Neoplasms
1
Mycosis Fungoides
1
Metastatic Urothelial Cell Cancer
1
Metastatic Solid Tumors
1
Interventions
Cyclophosphamide
24
fludarabine phosphate
22
Filgrastim
15
Gemcitabine
14
fludarabine
13
Rituximab
13
Brentuximab Vedotin
13
Peripheral Blood Stem Cell Transplantation
12
Whole-Body Irradiation
11
Vorinostat
11
Tacrolimus
11
Bortezomib
10
Mycophenolic Acid
9
Melphalan
9
Etoposide
9
Busulfan
9
Sirolimus
8
Lenalidomide
8
Azacitidine
8
Nivolumab
7
Dexamethasone
7
pembrolizumab
6
Radiotherapy
6
Cytarabine
6
Antilymphocyte Serum
6
romidepsin
5
aldesleukin
5
Panobinostat
5
Leucovorin
5
Doxorubicin
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Hodgkin Disease
×
avelumab
×
Clear all
NCT02603419
2020-04-24
JAVELIN HODGKINS
Pfizer
Phase 1
Terminated
34 enrolled
43 charts